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ABSTRACT 
Introduction The increasing complexity of drug regimens over time and the use of 
multiple medications exposes older patients to a greater risk of receiving inappropriate 
medications. The study aims to investigate whether drug burden index (DBI) and 
potentially inappropriate medications (PIMs) were associated with patient-reported 
health outcomes (PROs) in community-dwelling older adults (aged ≥60 years) in 
Malaysia.  
Methods DBI used to quantify patients’ exposure to anticholinergic and sedative 
medications in a cross-sectional sample of older individuals from the community 
pharmacy setting in Malaysia. PIMs (based on Beers criteria), potentially inappropriate 
prescribing (PIP; based on STOPP criteria) and polypharmacy (use of ≥ 5 concurrent 
medications) used to quantify exposure to in appropriate medications. PROs were 
investigated using the Groningen Frailty Indicator (GFI) for frailty, and Older People’s 
Quality of Life-35 (OPQOL) for quality of life (QOL). The adjusted associations between 
DBI, medication inappropriateness and PROs were analyzed. 
Results More than half of the study participants received ≥ 1 anticholinergic or sedative 
medication (mean 0.47/participant; range 0.0–2.14). Prevalence of frailty was low; 8.90% 
of patients with a mean GFI score of 1.67 (range 1–8) and was significantly and positively 
correlated with DBI (r 0.253; p = 0.003). In multivariate logistic regression, frailty was 
found to be significantly associated with the odds of receiving DBI-associated 
medications (odds ratio 1.44; 95% CI 1.02–2.02, p = 0.039). Non-significant associations 
between DBI and QOL domains, except significant and positive correlation between 
independence domain of OPQOL and PIPs.  
Conclusion The study indicates a significant relationship between drug burden measured 
by DBI, and frailty measured by GFI. The prescribers managing various medical 
conditions of older people should consider frailty and other relevant physical health 
parameters as important health outcomes. 
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Introduction  
The ageing population is poised to become one of the most significant social 
transformations of the 21st century [1]. The World Health Organization predicts an 
estimated growth of global aging population from 524 million in 2010 to 105 billion in 
2050 [2]. Similarly, in Malaysia, as of 2015, 8.0% of the total population consisted of 
people aged > 60 years [3]. With the decline in fertility and mortality rates, however, the 
proportion of older people will expand by 2030 and is predicted to account for 15.0% of 
the total population [1,2]. 
Aging is significantly associated with the development of comorbid chronic conditions, 
which warrants the use of multiple medications, as per clinical guidelines [3]. Aging is 
commonly characterized by the emergence of several complex health states, commonly 
called geriatric syndromes, which highlights unique and common features of health 
conditions in older people [4]. This includes frailty, urinary incontinence, falls, delirium 
and pressure ulcers [5-8]. Frailty leads to a state of vulnerability and impaired ability to 
adapt to external stressors [6], and increases the risk of dependency and adverse events 
(e.g. cognitive and functional status decline, disabilities, institutionalization and 
hospitalization) [6]. Frailty coupled with multiple impairments complicate treatment and 
limit drug choices among older people.  
Complexity of drug regimen among older people continues to increase over time, as 
multiple medications are required to treat a single condition. As a result, polypharmacy 
is prevalent among older people, with reports of over 45.9% urban community-dwelling 
older adults in Malaysia receiving ≥5 medications [9]. Polypharmacy is commonly 
associated with suboptimal prescribing, which is significantly linked to deterioration in 
physical functioning status [10,11]. Internationally, Gnjidic et al.investigated the 
association between the Drug Burden Index (DBI), a tool measuring an individual’s 
exposure to sedative and anticholinergic drugs, and the Beers Criteria, a measure of 
potentially inappropriate drug use, with function in older adults residing in self-care 
retirement villages [12]. Kojima et al. reviewed the association between frailty and quality 
of life (QOL) among community-dwelling older people [13]. The literature also vastly 
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discusses the improvement in quality of medicines use and patient-reported health 
outcomes (PROs) via medication reviews for older people [14], with Castelino et al.  
supporting such improvements when home medicines review services for community-
dwelling older people were performed by pharmacists [15]. However, these studies do 
not focus on the assessment of medication appropriateness and drug burden to optimize 
functional performance and abilities in frail individuals and those with poor QOL. In 
addition, there are limited studies investigating such associations among community-
dwelling older people in Malaysia (5,11). Hence, the aim of this study is to examine 
whether DBI and inappropriate medicines use were associated with PROs in community-
dwelling older adults in Malaysia. 
 
Methods  
Study design, participants and setting  
This was a cross-sectional study conducted among community-dwelling older people 
who visited community pharmacies between July and September 2017. This study 
assessed associations between DBI (i.e. exposure to anticholinergic and sedative 
medicines), medication inappropriateness and PROs in the community pharmacy 
setting. Community pharmacies from areas representing different geographic locations 
were selected because of their convenient accessibility and proximity to the researcher. 
In total, four community pharmacies, operated by private owners, in Kuala Lumpur and 
Selangor (both of which are in in peninsular Malaysia) participated in the study.   
Participants were included if they had been visiting a community pharmacy, were aged 
≥60 years, were mobile, had ≥ 1 long-term medical condition, had received ≥ 1 long-term 
medication, were articulate in English and provided informed consent to participate. An 
interviewer-administered comprehensive assessment form (CAF) was used to collect 
demographic data (age, sex, race, marital status, education level, occupation history, 
number of children and siblings, physical activity level, smoking and alcohol status), 
QOL, mental health status, frailty status, and medication and medical history, from 
participants.  
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Our investigation complies with the standards of the Helsinki declaration concerning 
investigation with human subjects. The International Medical University Joint-Committee 
on Research and Ethics (Project ID: BPI-1-14-(09)2017) provided ethical approval for 
the study. Permissions from individual community pharmacies were also obtained before 
data collection. Participants’ personal data were stored in a password-protected file 
accessible only to the researchers. No personal data was disclosed, and the study 
results are reported as de-identified data. 
Assessment of medication inappropriateness  
The inappropriateness of medications was assessed using the Beers criteria (2015), 
which identifies potentially inappropriate medications (PIMs), and the Screening Tool of 
Older Persons’ potentially inappropriate Prescriptions (STOPP) criteria (2014), which 
identifies potentially inappropriate prescribing (PIP) [16,17]. Both are based on a 
medicine-to-avoid list by expert consensus [16,17].  
The use of medicines use was primarily based on patients’ medical records obtained 
from each participating community pharmacy. The data collected included the name, 
dose, and dose instructions for all medications used in the 3 months prior to the start 
date of the study at each facility. Exposure to a PIM, PIP or DBI medication was defined 
as exposure to an affected medication during the 3-month period. 
Assessment of drug burden index  
The DBI was used to quantify individuals’ total exposure to anticholinergic and sedative 
medication, using the following formula [18-20]: 
𝐷𝐵𝐼 =
𝐷
𝐷 +  𝛿
 
where D is the daily dose taken by the individual within 24 h (derived from dosing 
instructions available through medical records), and δ is the minimum efficacious dose 
which was approved and registered by the Ministry of Health Malaysia (Formulari Ubat 
KKM (FUKKM, March 2016). The Malaysian product information and Monthly Index of 
Medical Specialties (MIMS Malaysia; 2017) were used to identify medications with 
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clinically significant anticholinergic and/or sedative effects. Complementary medications, 
health supplements and medications prescribed on a when required basis were excluded 
from the DBI calculations (see Supplementary Table for DBI calculation).  
Patient-reported health outcomes  
The PROs evaluated were the Groningen Frailty Indicator (GFI), Older People’s Quality 
of Life (OPQOL) inventory, and the Hospital Anxiety and Depression Scale (HADS). The 
GFI consists of 15 dichotomous items, ranging from a total score of 0 (normal activity 
without restrictions) to 15 (completely disabled); participants with scores ≥ 4 were 
considered frail [21]. We have validated the GFI tool and reported our findings elsewhere 
[22]. OPQOL was used to assess QOL in 9 domains: overall life, health, social 
relationships, independence, control over life, freedom, home, and neighborhood, 
psychological and emotional wellbeing, finance, and religion/ culture [23]. Total OPQOL 
scores range from 35 (worst possible QOL) to 175 (best possible QOL) [23]. In this study, 
polypharmacy was defined as ≥ 5 concurrent medications being dispensed at any one 
time during the study period, with participants’ medication details being obtained from 
the interview [24]. HADS was used to screen emotional disorders of participants in non-
psychiatric settings by detecting anxious and depressive states, which are the two most 
frequent distress expressions [25]. It consists of a list of questions, with scores ≥11 for 
either domain indicating the anxious and depressive states [25]. 
Sample size and sampling  
The estimated study sample size was 135, based on the percentage prevalence of 
Malaysian population aged ≥ 60 years, with a 95% confidence level and 4% margin of 
error [26]. About 170 older people from community pharmacies in the Kuala Lumpur and 
Klang Valley regions were approached. Of these, 135 participants who met the inclusion 
criteria and provided informed consent were included. Before each interview, consent 
(either verbal or written) was obtained after explaining research objectives to the 
participants who corresponded to the inclusion criteria. Each interview was conducted in 
the English language using interviewer-administered CAF. Participants were identified 
with the help of pharmacist working at the sampled pharmacies. 
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Statistical analysis  
The data were analyzed using the Statistical Package for Social Sciences (SPSS version 
24) ® with a significance level of 0.05. The collected data are presented as frequencies, 
percentages, means and standard deviations. Chi-square test was used to compare 
PROs and medication-related variables (e.g. frailty and polypharmacy; frailty and DBI). 
Spearman correlation was used to determine the underlying relationship between 
variables such as DBI, medication appropriateness and PROs. GFI, OPQOL, and HADS 
scores were changed to binary variables. The median split method was used to split total 
OPQOL scores (35 to 175) into binary variables (good and poor QOL) [27]. A HADS 
score of 7 was used to categorize cases and non-cases of depression and anxiety. 
Unadjusted and adjusted binary logistic regression models were used to examine 
associations between (1) exposure to a PIM according to the Beers Criteria (yes or no), 
(2) exposure to a PIP (yes or no) or (3) having a DBI>0 and GFI, OPQOL, and HADS 
measures (binary variables). The potential confounders were identified based on their 
association with main variables and based on a priori knowledge [16-20]. We determined 
variables necessary to control for a confounding effect and that includes age, sex, marital 
status, number of medications, PROs, and medication-related variables.  
 
Results  
Socio-demographic characteristics of participants  
A total of 135 community-dwelling older adults participated in this study. Female and 
Chinese participants constituted ≈46% and 64% of the total sampled population, 
respectively. The mean age of participants was 68.89 ± 6.14 years, with the majority of 
them (94 patients; 69.60%) being aged 60–69 years. Almost all participants (131; 
97.00%) were married (Table 1). 
Patient-reported health outcomes (PROs)  
About 9% of the participants fell into the frail category (defined as a GFI score of ≥4), 
with a mean score of 1.67 ± 1.387 (range 1-8). The mean total OPQOL score was 130.30 
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± 8.01 (range 109-157) with leisure and activities as the highest domain scored in 
OPQOL (Table 2). 
Use of medicines by the participants  
The mean number of medications per participant was 2.34 ± 1.37 (range 1-7). 
Polypharmacy (≥5 medications) was received by ≈8% (n = 11) of participants, and ≥ 1 
PIM or PIP by 8.90% (n=12) and 5.20% (n=7) of patients, respectively. About 59% (n=80) 
of the participants received ≥ 1 anticholinergic and/or sedative medication included in 
the DBI (mean 0.47/patient; range: 0–2.14; Table 3).  
Drug Burden Index, inappropriate medications and PROs 
Exposure to inappropriate medications (including PIMs, PIPs and polypharmacy) 
occurred in < 10% of the frail population in the community pharmacy setting. The 
difference in mean PIMs was statistically significant between frail and non-frail 
participants (0.13 vs 0.03, p=0.001). However, the differences in average PIPs and DBI 
between frail and non-frail participants were not significant. There was a significant and 
positive correlation of GFI with number of PIMs (r 0.255; p=0.003) and DBI (r 0.253; 
p=0.003) in the correlation analysis.  
In the total study population, being exposed to ≥1 PIM or PIP according to the Beers and 
STOPP Criteria was not significantly associated with the total OPQOL score when 
compared to not being exposed to a PIM or PIP. Among all OPQOL domains, the only 
significant and positive correlation was between the independence domain of OPQOL 
and number of PIPs (r 0.172; p=0.046). The correlation analysis also found a significant 
and positive relationship between DBI and polypharmacy (r 0.319; p=0.001).  
In the multivariate logistic regression, frailty was found to be significantly associated with 
the odds of receiving DBI-associated medications (odds ratio1.44; 95% CI: 1.02 – 2.02, 
p=0.039), as depicted in Table 4. Frailty was also significantly associated with exposure 
to a PIM in the unadjusted model, but became insignificant after adjustment for potential 
confounders. The OPQOL scores were associated with an increased risk of receiving 
DBI-associated medications, PIM and PIP, but their associations were not statistically 
significant.  
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Discussion  
The present study examines drug burden and its relationship with medication 
inappropriateness and PROs in community-dwelling older people in Malaysia. In this 
community-based study, frail older people were exposed to greater anticholinergic and 
sedative load than non-frail participants. As a result, frail participants have greater 
reported medication burden quantified by DBI compared with non-frail participants. 
Furthermore, the association remained significant even after adjustment for covariates. 
The findings from this study were consistent with studies conducted in different countries 
(USA, Australia and Finland), despite the differences in healthcare access and 
medication exposure [28-30]. According to some literature, the presence of frailty 
contributes to the development and progression of multiple chronic comorbidities [31]. 
As a result, older frail people experience greater complexity in medication regimen, which 
commonly involves anticholinergic and sedative medications. 
Rational prescribing among older people is complex due to lack of medication 
effectiveness and safety data in this age group [32,33], resulting in a high prevalence of 
inappropriate medication use among older people. More than half of the older people in 
this study were exposed to DBI-associated medications and there seemed to be a 
significant and positive correlation between GFI and medication inappropriateness. The 
findings from this study are consistent with a retrospective analysis conducted by 
Castelino et al. in older community-dwelling older individuals prior to a medication review 
intervention, in which the majority of participants were exposed to DBI-associated 
medications and one-third had PIMs [15]. This can be explained by age-related changes 
in pharmacokinetics and pharmacodynamics among older people [34]. Furthermore, the 
frail elderly people are also known to be more intolerant of medications than their fit 
counterparts [34, 35]. They have a diminished ability to adapt to changes with impaired 
homeostatic mechanisms and decrement in their hepatic metabolism. Indeed, they are 
expected to portray an exaggerated response to medications [35].  
Poorer QOL was also associated with medication inappropriateness. Although there was 
no statistically significant association identified between both parameters, there was a 
statistically significant association between medication inappropriateness and the 
10 
 
 
physical health domain measured by OPQOL-36. Harrison et al.  depicted similar 
findings in a cross-sectional study with a significant association between higher DBI and 
poorer QOL, as well as increasing PIMs and poorer QOL [36]. This can be explained by 
the nature of inappropriate medication use, which commonly leads to adverse outcomes 
that affects participants’ morbidity and QOL [37, 38]. In contrast, there was a statistically 
significant and negative association between medication inappropriateness and 
dependency. This, however, contradicts several studies that have reported a positive 
correlation between both parameters. This could be due to the setting of this study as 
the participants were non-institutionalized individuals with better health status [38, 39] 
than those in settings such as aged-care facilities, nursing homes and retirements 
villages [36, 37]. 
Many studies have investigated medication use and high-risk prescribing among 
community-dwelling older people [16,24,30,32,33]. However, to the authors’ knowledge, 
this was the first study in Malaysia (or the region) that investigated the association 
between medication burden and medication appropriateness. The study has shown 
statistically significant correlation between medication burden and medication 
inappropriateness. More participants with DBI > 0 than those who were not exposed to 
DBI-associated medications (DBI = 0) had inappropriate medication use, as shown by 
the proportions of patients exposed to a PIM (58.33 vs 41.67%). PIP (57.14 vs 42.86%) 
or polypharmacy (90.91 vs 9.09%). Anticholinergics and sedatives were common 
inappropriate medications prescribed among older people. 
There are several strengths to the study. Both implicit and explicit tools were used to 
measure medication appropriateness. Validated tools were used in this study to 
investigate medication appropriateness, drug burden and physical health outcomes. 
However, some limitations could affect the generalizability of the study findings. Firstly, 
the cross-sectional study design is not suitable to determine the nature of the temporal 
relationship between medication appropriateness, drug burden and physical function 
parameters as the exposure and outcome are assessed simultaneously. Secondly, low 
reliability in self-reported medication use, history and medical conditions may result in an 
underestimation of medication appropriateness and drug burden. Thirdly, DBI 
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calculations use the minimum recommended daily dose, which may vary depending on 
medication-related pharmacokinetic and pharmacodynamic differences, as well as inter-
individual variability. This could have caused biasness when determining the 
pharmacodynamic contribution of individual medications [19]. Fourthly, the use non-
probability sampling (convenience sample) may result in selection bias. Lastly, the 
unadjusted and adjusted effect sizes are generally biased in most studies except 
randomized studies. In general, as the sample size increases, the risk of getting biased 
r-squared would get smaller. We preferred logistic regression because an equivalent 
statistic to R-squared does not exist (depends on pseudo R-squared values). 
In conclusion, the present study found a significant relationship between high-risk 
prescribing (e.g. higher DBI-associated medications) and PROs such as frailty and QOL. 
However, exposures to both DBI and medication inappropriateness were not significantly 
associated with overall QOL. Medication inappropriateness measured by PIM, PIP and 
polypharmacy was higher among DBI-exposed participants. The prescribing of 
medications for managing various medical conditions among older people should 
consider frailty or other physical health parameters as part of a disease prognosis. 
Further longitudinal studies investigating the impact of drug burden due to suboptimal 
prescribing and its association with functional deterioration is important to study the 
nature of the association.  
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1 Socio-demographic parameters of participants (n=135) 
Variables No. of pts (%) 
Agea 
60 – 69 years 94 (69.60) 
70 – 79 years 34 (25.20) 
≥80 years  7 (5.20) 
Sex 
Female 62 (45.90) 
Male 73 (54.10) 
Race 
Chinese 87 (64.40) 
Malay 23 (17.00) 
Indian 24 (17.80) 
Marital status 
Married 131 (97.00) 
Single 4 (3.00) 
aMean age 68.89 years ± 6.14 (SD) 
Pts participants, SD standard deviation 
 
Table 2: Patient-reported health outcomes of participants (n=135) 
Variable Value Minimum Maximum 
Groningen Frailty Index scores (possible range: 0–15) 
Mean score ± SD 1.67 ±1.39 1 8 
No. of non-frail pts (score <4) (%) 123 (91.10)   
No of frail pts  (score ≥ 4) (%) 12 (8.90)   
Hospital Anxiety and Depression Scale scores  (possible range: 0 – 42)  
Mean total score  ± SD  5.49 ± 6.83 0 35 
Mean anxiety score (SD) 3.90 ± 4.54 0 21 
Mean depression score ± SD  1.59 ± 2.67 0 14 
No. of pts without anxiety (score 0-7) (%) 108 (80.00)   
No. of pts with anxiety (score 8-21) (%) 27 (20.00)   
No. of participants without depression (score 0-7) (%) 130 (96.30)   
No of pts with depression (score 8-21) (%) 5 (3.70)   
OPQOL scores  (possible range: 35–175) 
Mean total score ±  SD 130.30 ± 8.01 109 157 
No. of pts with good OPQOL (%) 61 (45.20)   
No. of pts with poor OPQOL (%) 74 (54.80)   
OPQOL domain scores ± SD  
Life overall (possible range: 4 – 20) 15.52 ± 2.36 8 20 
Health (possible range: 4 – 20) 15.34 ± 2.01 10 20 
Social relationships (possible range: 5 – 25) 15.94 ± 0.62 14 18 
Independence, control over like, freedom (possible range: 4 – 20) 16.09 ± 1.27 11 20 
Home and neighborhood (possible range: 4 – 20) 15.90 ± 1.55 12 20 
Psychological and emotional well-being (possible range: 4 – 20) 14.22 ± 1.28 11 20 
Financial circumstances (possible range: 4 – 20) 16.04 ± 2.40 8 20 
Leisure and activities (possible range: 6 – 30) 21.25 ± 1.94 15 25 
OPQOL Older Peoples’ Quality of Life version 36, pts participants, SD standard deviation  
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Table 3  Medicines use, drug burden and medication inappropriateness (n=135) 
Variables Value 
Mean no of medications per pt ± SD (range) 2.34 ± 1.37 (1–7) 
No. of pts receiving polypharmacy  (%) 11 (8.10) 
No. of pts exposed to a PIM  (%) 12 (8.90) 
Mean no. of PIMs per pt ± SD (range) 0.36± 0.13 (0–1) 
No. of pts exposed to a PIP (%) 7 (5.20) 
Mean no. of PIPs per pt ± SD (range) 0.02 ± 0.11(0–1) 
No. of pts with DBI > 0 (%) 80 (59.30) 
Mean DBI score ± SD (range) 0.47 ± 0.49 (0–2.14) 
DBI Drug Burden Index,  PIM potentially inappropriate medication, 
PIP potentially inappropriate prescribing, pt(s) participant(s), SD 
standard deviation   
 
Table 4 Unadjusted and adjusted odds ratios (95% CI) of reporting exposure to DBI, PIMs, and PIPs, by patients’ health 
outcomes (n=135) 
Variables Odds ratio (95% CI), p-valuea 
Polypharmacy DBI score > 0 Exposure to a 
PIM  
Exposure to PIP 
Unadjusted models 
Frailty (GFI score)  1.26 (0.87-1.82), 
0.213 
1.34 (1.01 – 1.80), 
0.048 
1.77 (1.24 – 2.58), 
0.002 
1.10 (0.66 – 1.81), 
0.719 
OPQOL score 1.00 (0.96-1.08), 
0.571 
0.99 (0.95-1.03), 
0.588 
0.95 (0.88 – 1.03), 
0.203 
1.04 (0.94 – 1.14), 
0.467 
Adjusted modelsb 
Frailty (GFI score) 1.18 (0.76 – 1.83), 
0.452 
1.44 (1.02 – 2.02), 
0.039 
1.56 (0.96 – 2.54), 
0.075 
2.02 (0.77 – 5.30), 
0.152 
OPQOL score 1.01 (0.92 – 1.10), 
0.924 
1.00 (0.94 – 1.05), 
0.936 
1.01 (0.92 – 1.10), 
0.842 
1.02 (0.92 – 1.14), 
0.688 
Referents were no polypharmacy, DBI = 0, no exposure to a PIM or PIP 
DBI Drug Burden Index, GFI  Groningen Frailty Index (range 0–15); OPQOL Older Peoples’ Quality of Life version 
36 (range 35–175), PIM potentially inappropriate medication, PIP potentially inappropriate prescribing 
aBolded values indicate statistically significant between-variable differences 
bOdds ratio adjusted for age, sex, marital status, no of medications, Hospital Anxiety and Depression Scale scores, 
OPQOL, GFI, polypharmacy, PIM, PIP, DBI. Classification method used was logistic 
 
 
